AXON Hires Silvia De Carvalho as New Clinical Studies Lead
Former Klick Health Senior Vice President of Activation Strategy, Silvia De Carvalho, moves to front AXON’s clinical studies practice globally as clinical studies lead. She brings almost two decades of healthcare marketing expertise.
De Carvalho started her career working with the clinical development teams at Sanofi to identify optimal protocols and product viability in the diabetes landscape.
“Silvia is a wonderful addition to the AXON team, not only bringing a strong strategic mind to our client business, but also a high level of ambition for what we can achieve,” said Ralph Sutton, international managing partner of AXON, and its parent company AVENIR GLOBAL.
De Carvalho will help shape how AXON will support patients, caregivers, healthcare professionals, and broader stakeholders navigate the healthcare industry.
“Building on a great foundation, I am excited to continue our growth journey alongside our clients. A first key area of focus for us will be an expansion on our digital engagement services and how we can help clients optimally recruit and engage patients and healthcare professionals within digital and decentralized trials, but also effectively embrace adaptive trial design. The second area of focus will be helping clients to reach diverse patient populations to reflect the communities who may benefit from their medicines," said De Carvalho.
Reference
AXON HIRES SILVIA DE CARVALHO AS NEW CLINICAL STUDIES LEAD. (2023, July 17). AXON.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
